Key Points
- CEO Martine Rothblatt sold 9,500 shares of United Therapeutics at an average price of $553.83, totaling about $5.26 million. After the sale, Rothblatt still directly owned 40,513 shares, a 19% reduction in the position.
- UTHR shares were down 2.2% and last traded at $544.62, below the CEO’s sale price. The stock remains near the upper end of its 52-week range, with a high of $609.35 and a low of $272.12.
- Recent earnings missed analyst expectations, with quarterly EPS of $5.82 versus the $7.00 consensus and revenue of $781.5 million versus $797.4 million expected. Despite the miss, analysts remain broadly constructive, with an average rating of Moderate Buy and a target price of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $553.83, for a total transaction of $5,261,385.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $22,437,314.79. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Stock Down 2.2%
Shares of UTHR stock opened at $544.62 on Tuesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock has a market capitalization of $23.12 billion, a PE ratio of 20.10, a P/E/G ratio of 1.81 and a beta of 0.60. The firm has a 50 day moving average of $566.86 and a two-hundred day moving average of $516.87.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same period in the prior year, the business earned $6.63 EPS. The business's quarterly revenue was down 1.6% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock valued at $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC purchased a new stake in United Therapeutics in the second quarter valued at $277,000. Cerity Partners LLC lifted its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock valued at $3,691,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia lifted its position in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
UTHR has been the topic of a number of analyst reports. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective on the stock. TD Cowen restated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $619.42.
View Our Latest Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
